FibroGen Inc. (NASDAQ:FGEN)’s share price traded down 5.7% during mid-day trading on Wednesday . The stock traded as low as $17.75 and last traded at $18.02, with a volume of 280,293 shares. The stock had previously closed at $19.11.

Several equities analysts have recently issued reports on the company. Credit Suisse Group AG reiterated a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research report on Tuesday, August 9th. Zacks Investment Research upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $33.25.

The stock’s market cap is $1.13 billion. The company has a 50 day moving average of $18.34 and a 200 day moving average of $18.32.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by $0.01. Equities analysts expect that FibroGen Inc. will post ($1.26) EPS for the current year.

In related news, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $18.99, for a total transaction of $512,730.00. Following the completion of the sale, the chief executive officer now owns 3,507,164 shares of the company’s stock, valued at approximately $66,601,044.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $18.38, for a total transaction of $694,727.24. Following the sale, the chief executive officer now directly owns 3,413,255 shares of the company’s stock, valued at approximately $62,735,626.90. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in FibroGen stock. California Public Employees Retirement System bought a new stake in FibroGen Inc. (NASDAQ:FGEN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 111,500 shares of the biopharmaceutical company’s stock, valued at approximately $3,397,000. California Public Employees Retirement System owned 0.18% of FibroGen as of its most recent SEC filing.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.